Spyre Therapeutics to Participate in Upcoming June Investor Conferences
Get Alerts SYRE Hot Sheet
Join SI Premium – FREE
WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:
Event: Jefferies Global Healthcare Conference – New York
Date: Wednesday, June 3, 2026
Fireside Time: 12:15 pm ET
Event: Goldman Sachs 47th Annual Global Healthcare Conference – Miami
Date: Monday, June 8, 2026
Fireside Time: 10:00 am ET
Members of the Spyre management team will also host one-on-one investor meetings during the conferences.
Live audio webcasts and replays of these events will be available on the Spyre investor events website at https://ir.spyre.com/events-and-presentations.
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, visit Spyre's website at www.spyre.com.
For Investors:
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
[email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Breaking into the Global Top Three for Premium Displays, Chinese Smartphone Brand iQOO Set to Unveil a Breakthrough Display Product
- Swoop wins WhistleOut Editor’s Pick for August, named best SIM-only mobile plan with at least 30GB
- Kvika banki hf.: Jón Birgir Jónsson appointed CEO of Kvika banki
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Goldman Sachs, Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share